A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma

International Journal of Clinical Pharmacy

Volumn 35, Issue 3, 2013, Pages 483-487

  Cecchi, Michele ^a   Vaiani, Monica ^a   Ceroti, Marco ^b   Banfi, Roberto ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b ISPO   (Italy)

Author keywords

Bevacizumab; Glioblastoma; Irinotecan; Off label

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; TUMOR GROWTH;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OFF-LABEL USE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878311930     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9765-0     Document Type: Article

References (12)

1. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-5.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
3. Nishikawa R. Standard therapy for glioblastoma - a review of where we are. Neurol Med Chir (Tokyo). 2010;50:713-9.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-9.
6. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
7. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-8.
8. European Medicines Agency. Refusal assessment report for Avastin. 2010 Available at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000582/WC500075000.pdf Accessed on 13 Dec 2012.
9. Giunta Regione Toscana. Delibera Giunta Regione Toscana N. 608. 2010 Available at: http://159.213.95.22/delibera-oncologia.php Accessed on 13 Dec 2012.
10. Trippoli S, Pelagotti F, Messori A, Vacca F, Vaiani M, Maltoni S. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs R D. 2003;4:285-91.
11. Palozzo AC. An Italian model to evaluate appropriateness and effectiveness of drugs. EJOP. 2011;5:24-5.
12. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci. 2012;19(12):1636-40.